Drug Profile
Research programme: human therapeutic antibodies - Merck & Co/MorphoSys
Latest Information Update: 24 Jan 2008
Price :
$50
*
At a glance
- Originator Merck & Co; MorphoSys
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 21 Dec 2005 Preclinical trials in Undefined in Germany (unspecified route)
- 21 Dec 2005 Preclinical trials in Undefined in USA (unspecified route)